Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.56 |
| ▸ | VEGFA | P15692 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481700 | 0.88 | GPR119 (0.55) | GPR119VEGFAEGLN1MEN1KMT2A | |
| SCHEMBL2514655 | 0.88 | VEGFA (0.54) | VEGFAEGLN1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL265853 | 0.86 | VEGFA (0.55) | VEGFAEGLN1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21198803 | 0.86 | VEGFA (0.55) | VEGFAEGLN1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16346589 | 0.86 | HDAC1 (0.58) | VEGFAEGLN1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31752806 | 0.85 | DRD2 (0.54) | GPR119MEN1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL2858333 | 0.85 | TP53 (0.58) | GPR119VEGFAEGLN1MEN1KMT2A | |
| SCHEMBL5536182 | 0.85 | VEGFA (0.68) | VEGFAEGLN1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2363123 | 0.85 | VEGFA (0.56) | VEGFAEGLN1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4938599 | 0.85 | VEGFA (0.56) | GPR119VEGFAEGLN1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2008154601-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | ACE, SARS1, ACE2 | GPR119 2774/4885VEGFA 983/4885EGLN1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.